This finding indicates that the ISGyP criteria can identify additional cases with potential gene amplification among those classified as HER2-low or HER2–0 by the ASCO/CAP criteria, which is consistent with the conclusion drawn from the uterine serous carcinoma cohort (Table 3). Here, ERBB2 is linked to endometrial serous adenocarcinoma.